Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to present at the following upcoming investor conferences:

• Cantor Global Healthcare Conference 2025, fireside chat on Friday, September 5, 2025 at 9:45 a.m. ET in New York
• Morgan Stanley 23^rd Annual Global Healthcare Conference, fireside chat on Monday, September 8, 2025 at 9:15 a.m. ET in New York

A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

About Dyne Therapeutics
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
[email protected]
781-317-0353

Media
Stacy Nartker 
[email protected]
781-317-1938

You May Also Be Interested In

• Orum Therapeutics Announces U.S. FDA Clearance of an IND Application for ORM-1153, a Novel CD123-GSPT1 Degrader-Antibody Conjugate
• Norton Manx R Earns Landmark International Design Excellence Award for Reimagining the Superbike
• JumpCube Launches Free Program to Set Up Claude on AWS and Support AI-Driven Transformation for Businesses in Texas